Comparative Pharmacology
Head-to-head clinical analysis: STAVUDINE LAMIVUDINE EFAVIRENZ versus STAVUDINE LAMIVUDINE W NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAVUDINE LAMIVUDINE EFAVIRENZ versus STAVUDINE LAMIVUDINE W NEVIRAPINE.
STAVUDINE; LAMIVUDINE; EFAVIRENZ vs STAVUDINE; LAMIVUDINE W/NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination antiretroviral: stavudine is a nucleoside reverse transcriptase inhibitor (NRTI); lamivudine is an NRTI; efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Stavudine and lamivudine are phosphorylated intracellularly to active triphosphate metabolites that compete with natural substrates and incorporate into viral DNA, causing chain termination. Efavirenz binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate thymidine triphosphate and by causing DNA chain termination after incorporation. Lamivudine is an NRTI that inhibits HIV-1 reverse transcriptase via similar mechanisms. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
One tablet (stavudine 30 mg + lamivudine 150 mg + efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
One tablet (stavudine 30 mg / lamivudine 150 mg / nevirapine 200 mg) orally twice daily.
None Documented
None Documented
Stavudine: 1.0-1.6 h (adults), 2.5-5.0 h (neonates). Lamivudine: 5-7 h (adults), 10-14 h (neonates). Efavirenz: 40-55 h (single dose), 52-76 h (multiple doses).
Stavudine: 0.9–1.6 h (normal renal function), prolonged in renal impairment; lamivudine: 5–7 h (adults), 2–4 h (children); nevirapine: 25–30 h (terminal, after multiple doses), allowing once-daily dosing.
Stavudine: 40% renal (unchanged), 60% biliary/fecal (metabolites). Lamivudine: 70% renal (unchanged), 30% fecal (metabolites). Efavirenz: 16-61% renal (metabolites), 14-34% fecal (unchanged).
Stavudine: 50% excreted unchanged in urine via glomerular filtration and active tubular secretion; lamivudine: ~70% excreted unchanged in urine via active secretion; nevirapine: ~80% metabolized by liver, with <5% excreted unchanged in urine (metabolites eliminated renally and fecally).
Category A/B
Category A/B
NRTI
NRTI